Idefirix (imlifidase) receives conditional approval in EU to desensitise kidney transplant patients with a highly sensitised immune system

Imlifidase is an immunosuppressant that reduces the level of donor specific antibodies, thus enabling transplantation. The approval covers the drug's use for adult kidney transplant patients with a positive crossmatch against an available deceased donor.

PharmaTimes